Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis-Reference-Cited by-同舟云学术

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis

Published:2018-08-01 Issue:15 Volume:57 Page:2217-2221
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kudo Fumiaki¹,Watanabe Yasutaka¹²,Iwai Yuki¹,Miwa Chihiro¹,Nagai Yoshiaki¹³,Ota Hiromitsu¹,Yabe Hiroki⁴,Demitsu Toshio⁵,Hagiwara Koichi¹³,Koyama Nobuyuki²,Koyama Shinichiro¹

Affiliation:

1. Department of Pulmonary Medicine, Jichi Medical University, Saitama Medical Center, Japan

2. Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Japan

3. Department of Pulmonary Medicine, Jichi Medical University, Japan

4. Department of Rheumatology, Jichi Medical University, Saitama Medical Center, Japan

5. Department of Dermatology, Jichi Medical University, Saitama Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/15/57_9381-17/_pdf

Reference16 articles.

1. 1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.

2. 2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.

3. 3. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60: 12-25, 2016.

4. 4. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151: 195-199, 2015.

5. 5. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol 12: 198-203, 2010.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review;Seminars in Arthritis and Rheumatism;2024-08

2. A case of dermatomyositis associated with atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma;Kanzo;2024-07-01

3. Autoimmune Phenomena in Cancer Patients Treated with Immune Checkpoint Inhibitors;Autoimmune Disorders;2024-05-03

4. Causes and Clinical Presentation of Drug-Induced Dermatomyositis;JAMA Dermatology;2024-02-01

5. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature;Autoimmunity Reviews;2023-08